Organon & Co. to Issue Quarterly Dividend of $0.02 (NYSE:OGN)

Key Points

• Organon & Co. declared a quarterly dividend of $0.02 per share, with an annualized yield of 0.9%, to be paid on September 11th to shareholders of record as of August 15th.
• The company reported earnings of $1.00 per share for the last quarter, exceeding estimates, with a revenue of $1.59 billion, demonstrating a slight decline of 0.8% compared to the previous year.
• Shares of Organon & Co. saw a 3.7% increase following the earnings report, trading at $8.72, with a market capitalization of $2.27 billion.

Organon & Co. (NYSE:OGN - Get Free Report) declared a quarterly dividend on Wednesday, August 6th, Wall Street Journal reports. Shareholders of record on Friday, August 15th will be paid a dividend of 0.02 per share on Thursday, September 11th. This represents a c) dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 15th.

Organon & Co. has a dividend payout ratio of 2.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect Organon & Co. to earn $3.74 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.1%.

Organon & Co. Stock Up 3.7%

Shares of NYSE:OGN traded up $0.32 on Wednesday, reaching $8.72. The company had a trading volume of 7,295,569 shares, compared to its average volume of 4,510,025. Organon & Co. has a twelve month low of $8.01 and a twelve month high of $23.10. The stock has a 50-day moving average price of $9.78 and a 200 day moving average price of $12.02. The stock has a market capitalization of $2.27 billion, a P/E ratio of 3.03, a P/E/G ratio of 1.00 and a beta of 0.60. The company has a quick ratio of 1.15, a current ratio of 1.67 and a debt-to-equity ratio of 16.49.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.06. Organon & Co. had a return on equity of 227.43% and a net margin of 11.92%. The business had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.55 billion. During the same quarter in the previous year, the firm earned $1.12 EPS. The firm's revenue was down .8% compared to the same quarter last year. On average, equities analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Institutional Trading of Organon & Co.

A number of hedge funds and other institutional investors have recently modified their holdings of OGN. SouthState Corp grew its stake in shares of Organon & Co. by 1,857.0% in the second quarter. SouthState Corp now owns 3,914 shares of the company's stock worth $38,000 after purchasing an additional 3,714 shares during the last quarter. Bryce Point Capital LLC bought a new stake in shares of Organon & Co. in the second quarter worth $465,000. Aviance Capital Partners LLC bought a new stake in Organon & Co. during the second quarter valued at $599,000. Haven Private LLC bought a new stake in Organon & Co. during the second quarter valued at $113,000. Finally, Impact Partnership Wealth LLC boosted its position in Organon & Co. by 26.3% during the second quarter. Impact Partnership Wealth LLC now owns 18,418 shares of the company's stock valued at $178,000 after acquiring an additional 3,838 shares during the last quarter. Institutional investors own 77.43% of the company's stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.